Avalo Therapeutics, Inc. (AVTX)
NASDAQ: AVTX · Real-Time Price · USD
10.90
-0.15 (-1.36%)
Nov 20, 2024, 4:00 PM EST - Market closed

Company Description

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States.

The company’s drug candidates include AVTX-009, an Anti-IL-1β monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.

It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases.

The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021.

Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Avalo Therapeutics, Inc.
Avalo Therapeutics logo
Country United States
Founded 2011
IPO Date Oct 15, 2015
Industry Biotechnology
Sector Healthcare
Employees 19
CEO Garry Neil

Contact Details

Address:
540 Gaither Road, Suite 400
Rockville, Maryland 20850
United States
Phone 410-522-8707
Website avalotx.com

Stock Details

Ticker Symbol AVTX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001534120
CUSIP Number 05338F108
ISIN Number US05338F3064
Employer ID 45-0705648
SIC Code 2834

Key Executives

Name Position
Dr. Garry A. Neil M.D. Chairman of the Board, President and Chief Executive Officer
Dr. Solomon H. Snyder M.D. Founder and Chairman of Scientific Advisory Board
Dr. Barbara S. Slusher Ph.D. Founder and Member of Scientific Advisory Board
Paul C. Varki J.D., M.P.H Chief Legal Officer
Dr. Lisa Hegg Ph.D. Senior Vice President of Program Management, Corporate Infrastructure and Clinical Operations
Colleen Matkowski Senior Vice President of Global Regulatory Affairs and Quality Assurance
Dr. Dino C. Miano Ph.D. Senior Vice President of CMC and Technical Operations
Dr. Mittie Doyle FACR, M.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
Nov 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 12, 2024 8-K Current Report
Nov 7, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 7, 2024 S-8 Securities to be offered to employees in employee benefit plans
Nov 7, 2024 S-8 Securities to be offered to employees in employee benefit plans
Nov 7, 2024 10-Q Quarterly Report
Nov 7, 2024 8-K Current Report
Oct 8, 2024 8-K Current Report
Oct 7, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals